TW202304430A - 醫藥組合物及其用途 - Google Patents

醫藥組合物及其用途 Download PDF

Info

Publication number
TW202304430A
TW202304430A TW111112897A TW111112897A TW202304430A TW 202304430 A TW202304430 A TW 202304430A TW 111112897 A TW111112897 A TW 111112897A TW 111112897 A TW111112897 A TW 111112897A TW 202304430 A TW202304430 A TW 202304430A
Authority
TW
Taiwan
Prior art keywords
optionally substituted
alkyl
group
ceftibuten
membered
Prior art date
Application number
TW111112897A
Other languages
English (en)
Chinese (zh)
Inventor
大衛 Ｃ 格里菲斯
奧爾加 洛莫夫斯卡亞
伊麗莎白 Ｅ 摩根
杰弗瑞 Ｓ 洛蒂特
Original Assignee
美商Ｑｐｅｘ生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商Ｑｐｅｘ生物製藥股份有限公司 filed Critical 美商Ｑｐｅｘ生物製藥股份有限公司
Publication of TW202304430A publication Critical patent/TW202304430A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW111112897A 2021-04-05 2022-04-01 醫藥組合物及其用途 TW202304430A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170936P 2021-04-05 2021-04-05
US63/170,936 2021-04-05

Publications (1)

Publication Number Publication Date
TW202304430A true TW202304430A (zh) 2023-02-01

Family

ID=83545863

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111112897A TW202304430A (zh) 2021-04-05 2022-04-01 醫藥組合物及其用途

Country Status (11)

Country Link
US (1) US20240197750A1 (enExample)
EP (1) EP4319760A4 (enExample)
JP (1) JP2024512793A (enExample)
KR (1) KR20230167077A (enExample)
CN (1) CN117157078A (enExample)
AU (1) AU2022254114A1 (enExample)
BR (1) BR112023020348A2 (enExample)
CA (1) CA3212788A1 (enExample)
MX (1) MX2023011483A (enExample)
TW (1) TW202304430A (enExample)
WO (1) WO2022217199A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252351A1 (en) * 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
AU2017290060B2 (en) * 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
AU2017295866A1 (en) * 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
DK3886798T3 (da) * 2018-11-29 2026-04-20 Basilea Pharmaceutica Int Ag Allschwil Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf
US12636297B2 (en) * 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP4021443A1 (en) * 2019-08-29 2022-07-06 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Also Published As

Publication number Publication date
MX2023011483A (es) 2023-10-03
US20240197750A1 (en) 2024-06-20
EP4319760A1 (en) 2024-02-14
WO2022217199A1 (en) 2022-10-13
CN117157078A (zh) 2023-12-01
KR20230167077A (ko) 2023-12-07
CA3212788A1 (en) 2022-10-13
AU2022254114A1 (en) 2023-09-21
EP4319760A4 (en) 2025-01-08
BR112023020348A2 (pt) 2023-11-21
JP2024512793A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
US20240197750A1 (en) Ceftibuten dosing regimens
JP2023061946A (ja) β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
KR102789783B1 (ko) 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
US6221864B1 (en) Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
TW202114706A (zh) 硼酸衍生物以及其治療用途
TW202317588A (zh) 化合物的結晶型及其用途與製備方法以及組成物
CN119233823A (zh) 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
JP5339840B2 (ja) 抗ｘｄｒ−ｔｂ薬、抗ｍｄｒ−ｔｂ薬、及び併用抗結核薬
US6426369B1 (en) Oxethazaine as antimicrobial agent
AU2021220445B2 (en) Novel medicament for treating hepatic encephalopathy
JPH0152366B2 (enExample)
US20200237744A1 (en) Antimicrobial Compositions with Effervescent Agents
HK1044707B (en) Monthly doses of glycopeptide antibiotics for long-term prevention of streptococcus pneumoniae infections
JP2835547B2 (ja) 糖尿病治療剤
HK40078840A (en) Novel medicament for treating hepatic encephalopathy
WO2018016596A1 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
JP3685508B2 (ja) 抗ウレアーゼ剤
JP2000080031A (ja) 抗菌剤
JP2000239163A (ja) 腸疾患の治療剤
RU2314808C2 (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JPH03161440A (ja) 抗菌剤
WO2018012634A1 (ja) 不飽和複素５員環含有化合物を含有する肺高血圧症の予防又は治療剤
WO1996008247A1 (en) Anti-helicobacter agent
HK1133402A (en) New indications for direct thrombin inhibitors in the cardiovascular field
JPH0469339A (ja) 抗エイズウィルス剤